Online citations, reference lists, and bibliographies.
← Back to Search

Precocious Puberty Therapeutic Management: GnRH Analogs Treatment

C. Bouvattier
Published 2016 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
GnRH analog therapy is an effective treatment for central precocious puberty. The therapeutic management of central precocious puberty should be discussed on clinical criteria (rapidly progressive puberty, advance bone age), biological criteria (LH, inhibin B, estradiol), and ultrasound criteria (uterine length, ovarian volume). The optimal timing of treatment discontinuation has not been clearly evaluated. The average age of discontinuation is around 11 years, the physiological age of puberty in girls. Menarche occurs 12–18 months after the end of treatment. Clinical pubertal signs reappear a few months after the end of the treatment. Compromise of adult height, early menarche, and social and behavioral implications is often a concern for these patients.
This paper references
10.1056/NEJM198112243052602
Short-term treatment of idiopathic precocious puberty with a long-acting analogue of luteinizing hormone-releasing hormone. A preliminary report.
F. Comite (1981)
10.1056/NEJMCP0800459
Precocious puberty.
J. Carel (1986)
10.1016/S0022-3476(05)81162-X
Two-year results of treatment with depot leuprolide acetate for central precocious puberty.
E. Neely (1992)
10.1016/S0022-3476(05)81720-2
Local reactions to depot leuprolide therapy for central precocious puberty.
P. Manasco (1993)
10.1210/JCEM.80.2.7852518
Long-term effect of gonadotropin-releasing hormone agonist therapy on final and near-final height in 26 children with true precocious puberty treated at a median age of less than 5 years.
D. Paul (1995)
10.1016/S0022-3476(95)70255-5
Spontaneous serum gonadotropin concentrations in the evaluation of precocious puberty.
E. Neely (1995)
A single-sample, subcutaneous gonadotropin-releasing hormone test for central precocious puberty.
K. L. Eckert (1996)
10.1210/JCEM.84.2.5430
Unsustained or slowly progressive puberty in young girls: initial presentation and long-term follow-up of 20 untreated patients.
M. Palmert (1999)
10.1530/EJE.0.1410140
Analysis of the factors affecting auxological response to GnRH agonist treatment and final height outcome in girls with idiopathic central precocious puberty.
T. Arrigo (1999)
10.1210/JCEM.84.12.6204
Is obesity an outcome of gonadotropin-releasing hormone agonist administration? Analysis of growth and body composition in 110 patients with central precocious puberty.
M. Palmert (1999)
10.1210/JCEM.84.6.5647
Final height after long-term treatment with triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. French study group of Decapeptyl in Precocious Puberty.
J. Carel (1999)
10.1210/JCEM.84.10.6032
Lack of effect of GnRH agonists on final height in girls with advanced puberty: a randomized long-term pilot study.
C. Bouvattier (1999)
10.1210/JCEM.84.2.5533
Precocious puberty: who has it? Who should be treated?
K. Klein (1999)
10.1159/000053237
Serum Inhibin A and Inhibin B in Central Precocious Puberty before and during Treatment with GnRH Agonists
A. Sehested (2000)
10.1210/JCEM.85.11.6951
Boys with precocious puberty due to hypothalamic hamartoma: reproductive axis after discontinuation of gonadotropin-releasing hormone analog therapy.
P. Feuillan (2000)
10.1515/JPEM.2000.13.S1.687
Etiology of Central Precocious Puberty in Males: The Results of the Italian Study Group for Physiopathology of Puberty
V. De Sanctis (2000)
10.1515/JPEM.2000.13.S1.723
Pharmacokinetics and Pharmacodynamics of GnRH Agonists: Clinical Implications in Pediatrics
N. Lahlou (2000)
10.1210/JCEM.86.9.7852
Sexual precocity in boys: accelerated versus slowly progressive puberty gonadotropin-suppressive therapy and final height.
L. Lazar (2001)
10.1210/JCEM.86.10.7915
Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience.
K. Klein (2001)
10.1046/j.1365-2265.2001.01229.x
Central precocious puberty: clinical and laboratory features *
W. Chemaitilly (2001)
10.1542/PEDS.109.1.61
Central precocious puberty in girls: an evidence-based diagnosis tree to predict central nervous system abnormalities.
M. Chalumeau (2002)
10.1542/PEDS.110.5.897
Secondary sexual characteristics in children with cerebral palsy and moderate to severe motor impairment: a cross-sectional survey.
G. Worley (2002)
10.1159/000063209
Effect of Gonadotropin-Releasing Hormone Agonist Treatment in Boys with Central Precocious Puberty: Final Height Results
D. Mul (2002)
10.1210/JC.2001-020243
Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25 mg).
Jean-Claude Carel (2002)
10.1053/BEEM.2002.0188
Treatment of central precocious puberty.
C. Partsch (2002)
10.1067/S0022-3476(03)00328-7
Selecting girls with precocious puberty for brain imaging: validation of European evidence-based diagnosis rule.
M. Chalumeau (2003)
10.1002/uog.154
Pelvic ultrasound and color Doppler findings in different isosexual precocities
C. Battaglia (2003)
10.1093/HUMUPD/DMH012
Precocious puberty and statural growth.
Jean-Claude Carel (2004)
10.1007/BF01954267
Pelvic ultrasonography: Early differentiation between isolated premature thelarche and central precocious puberty
H. Haber (2005)
10.1007/S10578-004-3489-2
Precocious Puberty in Adolescent Girls: A Biomarker of Later Psychosocial Adjustment Problems
L. Tremblay (2005)
10.1159/000084098
Very long-term follow-up of girls with early and late menarche.
Thérese Johansson (2005)
10.1542/peds.2005-0012
Prevalence and Incidence of Precocious Pubertal Development in Denmark: An Epidemiologic Study Based on National Registries
G. Teilmann (2005)
10.1530/EJE.1.02056
Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty.
Jean-Claude Carel (2006)
10.1016/j.mce.2006.04.012
Long-term GnRH agonist treatment for female central precocious puberty does not impair reproductive function
S. Heger (2006)
10.1530/EJE.1.02151
Ultrasonographic and clinical parameters for early differentiation between precocious puberty and premature thelarche.
L. de Vries (2006)
10.1210/JC.2006-1569
Assessment of basal and gonadotropin-releasing hormone-stimulated gonadotropins by immunochemiluminometric and immunofluorometric assays in normal children.
E. M. Resende (2007)
10.1136/adc.2007.115709
Suppression of menstruation in adolescents with severe learning disabilities
A. Albanese (2007)
10.1210/JC.2007-0321
Growth pattern and final height after cessation of gonadotropin-suppressive therapy in girls with central sexual precocity.
L. Lazar (2007)
10.1530/EJE-08-0814
The use of GnRH agonists in precocious puberty.
D. Mul (2008)
10.1186/1471-2431-8-27
Idiopathic central precocious puberty in girls: presentation factors
Géraldine Prété (2008)
10.1111/j.1745-7262.2008.00409.x
Treatment of central precocious puberty by GnRH analogs: long-term outcome in men.
S. Bertelloni (2008)
10.1542/peds.2008-1783
Consensus Statement on the Use of Gonadotropin-Releasing Hormone Analogs in Children
J. Carel (2009)
10.1176/appi.ajp.2010.09081190
Outcomes of early pubertal timing in young women: a prospective population-based study.
William E. Copeland (2010)
10.1159/000308172
Effect of Treatment with Cyproterone Acetate on Uterine Bleeding at the Beginning of GnRH Analogue Therapy in Girls with Idiopathic Central Precocious Puberty
S. Seminara (2010)
10.1210/jc.2010-1025
Central precocious puberty in children living in Spain: incidence, prevalence, and influence of adoption and immigration.
L. Soriano-Guillén (2010)
10.1210/jc.2009-0793
The efficacy and safety of gonadotropin-releasing hormone analog treatment in childhood and adolescence: a single center, long-term follow-up study.
M. A. Magiakou (2010)
10.1210/jc.2010-2745
Diagnostic work-up of 449 consecutive girls who were referred to be evaluated for precocious puberty.
S. S. Mogensen (2011)
10.1016/j.fertnstert.2012.07.1118
Serum levels of antimüllerian hormone in early maturing girls before, during, and after suppression with GnRH agonist.
C. Hagen (2012)
10.1210/jc.2013-1024
Treatment and outcomes of precocious puberty: an update.
J. Fuqua (2013)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar